Trial Search Results

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

This clinical trial studies the use of sodium fluorine-18 (18F-NaF) plus fluorine-18 (18F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/ whole body magnetic resonance imaging (WBMRI) to detect skeletal metastases in patients with stage III-IV breast cancer or stage II-IV prostate cancer.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Procedure: Bone scan
  • Drug: 99mTc-methyl diphosphonate
  • Procedure: Positron Emission Tomography (PET) scan
  • Drug: 18F-Fludeoxyglucose (18F-FDG)
  • Procedure: Computed Tomography (CT) scan
  • Drug: 18F-Sodium Fluoride (18F-NaF)
  • Procedure: Whole Body Magnetic Resonance Imaging (WB-MRI) scan
  • Drug: Gadopentetate dimeglumine
  • Drug: Gadofosveset
  • Drug: Gadobutrol


Phase 2


All patients were enrolled after receiving a regular medical care bone scan using the
radiolabel 99mTc-methyl diphosphonate (t99-MDP).


   - ≥ 18 years old at the time of the drug administration

   - ≥ Stage 3 breast cancer OR ≥ stage 2 prostate cancer OR prostate-specific antigen
   (PSA) > 10 micrograms/L OR recurrent breast or prostate cancer

   - Capable of complying with study procedures

   - Able to remain still for duration of imaging procedure (about one hour)

   - Written informed consent


   - Pregnant or nursing

   - Metallic implants that contraindicate MRI

   - Renal function impairment that contraindicates MRI

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study